Table 1 Efficacy input parameters
Parameter | Palivizumab (SE) | No prophylaxis (SE) | Distribution in PSA | Source |
|---|---|---|---|---|
First year (decision tree) | ||||
MA-RSV risk, % | 1.9 (0.4) | 8.1 (1.6) | Beta | MAKI trial (2013, Feltes et al. (2003) |
RSV-H risk, % | 5.3 (0.9) | 9.7 (1.9) | Beta | Feltes et al. (2003) |
RSV-H: Immediate surgery, % | 11.1 (4.0) | 11.1 (4.0) | Beta | Altman et al. (2000) |
RSV-H: No immediate surgery, % | 88.9 (17.8) | 88.9 (17.8) | Beta | Altman et al. (2000) |
No surgery, % | 39.3 (7.9) | 39.3 (7.9) | Beta | Altman et al. (2000) |
Delayed surgery, % | 60.7 (6.5) | 60.7 (6.5) | Beta | Altman et al. (2000) |
Inpatient vs discharged before delayed surgery, % | 33 vs 67 (8.1) | 33 vs 67 (8.1) | Beta | Expert opinion* |
Case fatality, % | 5.2 (0.9) | 5.2 (0.9) | Beta | Szabo et al. (2013) |
CHD-specific background mortality (first 20 years) | age-specific mortality | age-specific mortality | Fixed | Tennant et al. (2010) |
CHD-specific background mortality (beyond 20 years) | age-specific mortality | age-specific mortality | Fixed | Diller et al. (2015), National mortality statistics (Spain, 2012) |
Proportions of respiratory sequelae (used for transition probability calculations, see Table 2) | ||||
MA-RSV: | ||||
Asthma, % | 10.3 (1.1) | 10.3 (1.1) | Beta | Stein et al. (1999) |
Allergic sensitization, % | 37.4 (3.9) | 37.4 (3.9) | Beta | Sigurs et al. (2010) |
RSV-H: | ||||
Asthma, % | 32.6 (6.9) | 32.6 (6.9) | Beta | Stein et al. (1999) |
Allergic sensitization, % | 43.5 (7.3) | 43.5 (7.3) | Beta | Sigurs et al. (2010) |
Other parameter | ||||
Nosocomial infection, % | 6.1 (0.6) | 6.1 (0.6) | Beta | Ehlken et al. (2005) |